The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma
Official Title: A Phase II Study of Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma Patients
Study ID: NCT06329869
Brief Summary: The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.
Detailed Description: Overexpression of Trop-2 was detected in ESCC compared with esophageal dysplasia. The investigators hypothesize that sacituzumab govitecan, by targeting Trop-2 which has been reported to be overexpressed in esophageal squamous cell carcinoma tumors, should have significant clinical activity in patients with advanced esophageal squamous cell carcinoma.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Chih-Hung Hsu, M.D., Ph.D.
Affiliation: National Taiwan University Hospital
Role: PRINCIPAL_INVESTIGATOR